Top Infectious Disease Diagnostics Companies

Infectious Disease Diagnostics Market size was valued at USD 22.94 Billion in 2023 and is poised to grow from USD 24.82 Billion in 2024 to USD 46.62 Billion by 2032, growing at a CAGR of 8.20% during the forecast period (2025-2032).

The competitive scenario of the infectious disease diagnostics market is characterized by established global players, emerging companies and local organizations all contributing to the growth of the industry by innovative a manufacture, partnerships and expansion of strategies. Major manufacturers such as Abbott Laboratories, Roche Diagnostics, Becton, Dickinson & Company (BD), and Biomeriex are market leaders, offering a range of diagnostic solutions from molecular diagnostics to point-of-care testing (POCT). These companies have strengthened their market positions through extensive divisions, strong R&D investments and global distribution networks. 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Abbott (US) ', 'bioMérieux (France) ', 'Siemens Healthineers AG (Germany) ', 'Danaher (US) ', 'Thermo Fisher Scientific Inc. (US) ', 'Hologic, Inc. (US) ', 'Becton, Dickinson and Company (US) ', 'Revvity (US) ', 'Qiagen (Netherlands) ', 'Seegene Inc. (South Korea) ', 'QuidelOrtho Corporation (US) ', 'Grifols, S.A. (Spain) ', 'DiaSorin S.p.A. (Italy) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Sysmex Corporation (Japan) ', 'OraSure Technologies (US) ', 'Co-Diagnostics, Inc. (US) ', 'Trinity Biotech (Ireland) ', 'Genetic Signatures Ltd. (Australia) ', 'Epitope Diagnostics, Inc. (US) ', 'Trivitron Healthcare (India) ', 'ELITech Group (France) ', 'Meril Life Sciences Pvt. Ltd. (India) ', 'InBios International, Inc. (US) ', 'Uniogen Oy (Finland) ', 'Vela Diagnostics (Singapore)'

The rise in infectious sicknesses which includes HIV, tuberculosis, hepatitis. COVID-19 is driving the demand for advanced diagnostics globally. These sicknesses require accurate, early diagnosis for powerful treatment, and wearable injectors, incorporated with diagnostic technologies, provide progressive solutions. Additionally, the increasing attention on disorder surveillance and outbreak monitoring has amplified the need for on-hand and speedy diagnostics, assisting marketplace expansion. 

Increase in Point-of-Care Testing (POCT): A major trend in the infectious disease diagnostics market is the rise of POCT. Changes in the decentralization of health care delivery and rapid on-demand analysis have led to the adoption of easy-to-use portable diagnostic kits. This trend does not appear to give rise to not only increases patient attendance but also reduces stress on hospitals by allowing outpatient testing. 

North America region in the infectious disease diagnostics market accounted for 38.49% of the global market in 2023. The industry is expected to keep expanding at lucrative growth during the forecast period with favorable & flexible regulatory framework. Presence of major manufacturers offering new IVD products, more testing and focus on disease management are the major factors driving the North America region. For example, in August 2023, the FDA provided a BD Vaginal Panel in the BD COR program to identify infectious agents that cause vaginal infections. The market for infectious diseases in the United States is expected to grow during the forecast period. The outbreak of COVID-19 dramatically changed the market landscape of diagnostics as companies engaged in test development with faster and more efficient turnaround times.